Hydrochloric Acid

Hydrochloric Acid

SCHEMBL2177775

Cc1cc[n+](CCOCCOCCOCC[n+]2ccc(C)c(C)c2)cc1C.[Cl-].[Cl-]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 3/20 0.47
CHRNA7 P36544 4/20 0.50
CHRNA10 Q9GZZ6 4/20 0.50
CHRNA9 Q9UGM1 4/20 0.50
BCHE P06276 3/20 0.50
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30968372 1.00 CHRNA7 (0.50) CHRNA7CHRNA10CHRNA9BCHEGRIN1
SCHEMBL4399009 0.98 BCHE (0.52) CHRNA7CHRNA10CHRNA9BCHEGRIN1
Iodide SCHEMBL26093412 0.96 CHRNA7 (0.50) CHRNA7CHRNA10CHRNA9BCHEGRIN1
Iodide SCHEMBL26093408 0.96 CHRNA7 (0.50) CHRNA7CHRNA10CHRNA9BCHEGRIN1
Hydrochloric Acid SCHEMBL26091078 0.96 CHRNA7 (0.50) CHRNA7CHRNA10CHRNA9BCHEGRIN1
Hydrochloric Acid SCHEMBL3313461 0.87 CHRNA7 (0.44) CHRNA7CHRNA10CHRNA9BCHEGRIN1
Hydrochloric Acid SCHEMBL2177070 0.79 ACHE (0.53) BCHEGRIN1GRIN2AACHE
SCHEMBL4399002 0.77 ACHE (0.55) BCHEGRIN1GRIN2AACHE
Hydrochloric Acid SCHEMBL2176293 0.76 BCHE (0.49) BCHEGRIN1GRIN2AACHE
Water SCHEMBL31247957 0.75 CHRNA7 (0.67) CHRNA7CHRNA10CHRNA9BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160340335-A9 METHOD OF TREATING NEUROPATHIC PAIN UNIVERSITY OF UTAH (US) 2016-11-24 US claimed
US-20160279119-A9 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2016-09-29 US claimed
US-20140011836-A1 METHOD OF TREATING NEUROPATHIC PAIN UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-01-09 US claimed
US-20110166177-A1 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-07-07 US claimed
US-20100069432-A1 Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-03-18 US claimed
EP-4419206-B1 COMPOUNDS FOR THE TREATMENT OF MALARIA FUNDACIO INST DE BIOENGINYERIA DE CATALUNYA (ES) 2025-09-17 EP disclosed
US-20240415825-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA Fundación Privada Instituto De Salud Global Barcelona (ES) 2024-12-19 US disclosed
EP-4419206-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA Fundacio Institut de Bioenginyeria de Catalunya (ES) 2024-08-28 EP disclosed
WO-2023067170-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) 2023-04-27 WO disclosed
US-10071982-B2 Method of treating neuropathic pain UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2018-09-11 US disclosed
US-20160340335-A9 METHOD OF TREATING NEUROPATHIC PAIN UNIVERSITY OF UTAH (US) 2016-11-24 US disclosed
US-9499518-B2 Bis-quaternary ammonium salts as pain modulating agents UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2016-11-22 US disclosed
US-20160279119-A9 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2016-09-29 US disclosed
US-20140011836-A1 METHOD OF TREATING NEUROPATHIC PAIN UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-01-09 US disclosed
US-8178678-B2 Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2012-05-15 US disclosed
US-20110166177-A1 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-07-07 US disclosed
US-20100069432-A1 Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240415825-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA ABAT, GLS2, CPS1 ACHE 148/4885CHRNA7 4201/4885CHRNA10 4086/4885
US-20110166177-A1 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS RELA, FHIT, OPRL1 ACHE 163/4885CHRNA7 448/4885CHRNA10 265/4885
US-10071982-B2 Method of treating neuropathic pain INA, GAP43, ACHE ACHE 3/4885CHRNA7 157/4885CHRNA10 126/4885
US-20160340335-A9 METHOD OF TREATING NEUROPATHIC PAIN INA, GAP43, ACHE ACHE 3/4885CHRNA7 157/4885CHRNA10 126/4885
US-20160279119-A9 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS RELA, FHIT, OPRL1 ACHE 163/4885CHRNA7 448/4885CHRNA10 265/4885
US-20100069432-A1 Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors CHRNA2, CHRNA5, CHRNA4 ACHE 22/4885CHRNA7 7/4885CHRNA10 4/4885
US-20140011836-A1 METHOD OF TREATING NEUROPATHIC PAIN INA, GAP43, ACHE ACHE 3/4885CHRNA7 157/4885CHRNA10 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.